Date: 2016-10-18
Type of information: Recruitment of the first patient
phase: 3
Announcement: recruitment of the first patient
Company: Cytokinetics (USA - CA)
Product: tirasemtiv
Action mechanism:
Disease: amyotrophic lateral sclerosis (ALS)
Therapeutic area: Neurodegenerative diseases - Rare diseases
Country:
Trial
details: VIGOR-ALS is an open-label extension trial of tirasemtiv in patients with ALS who completed participation in VITALITY-ALS. The primary endpoint of the trial is the incidence of adverse events in the patient population. Secondary endpoints include the time to events such as death or the first use of assisted ventilation or respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ?22 hours per day for ?10 consecutive days); decline from baseline in percent predicted slow vital capacity (SVC), ALS functional rating scale-revised (ALSFRS-R); and the slope of change from baseline in percent predicted SVC and ALSFRS-R. Following enrollment, patients will begin dosing of tirasemtiv 125 mg twice daily (250 mg/day) for a period of 4 weeks and will titrate to their maximum tolerated dose (based on tolerability), to no higher than 250 mg twice daily (500 mg/day).
Latest
news: * On October 18, 2016, Cytokinetics announced the first patient has been enrolled in VIGOR-ALS (Ventilatory Investigations in Global Open-Label Research in ALS), an open-label extension clinical trial designed to assess the long-term safety and tolerability of tirasemtiv, in patients with ALS who have completed their participation in VITALITY-ALS, the Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity (SVC) and other measures of respiratory and skeletal muscle function.
